CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-908-5179500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions
What is CorMedix's stock symbol?
CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."
How were CorMedix's earnings last quarter?
CorMedix Inc. (NYSEAMERICAN:CRMD) announced its quarterly earnings data on Tuesday, August, 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The biotechnology company earned $0.01 million during the quarter, compared to the consensus estimate of $0.10 million. View CorMedix's Earnings History.
What price target have analysts set for CRMD?
2 equities research analysts have issued 12 month target prices for CorMedix's shares. Their predictions range from $3.50 to $6.00. On average, they anticipate CorMedix's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 182.7% from the stock's current price. View Analyst Price Targets for CorMedix.
What is the consensus analysts' recommendation for CorMedix?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CorMedix.
What are Wall Street analysts saying about CorMedix stock?
Here are some recent quotes from research analysts about CorMedix stock:
- 1. According to Zacks Investment Research, "CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix's goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company's therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin®, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin®. CorMedix Inc. is based in Summit, New Jersey. " (2/12/2019)
- 2. HC Wainwright analysts commented, "We derive a value of $470M for Neutrolin using a 12% discount rate and 90% probability of success, along with a 23% effective tax rate, or a price per share of $3.50, taking into account $150M from additional value drivers (ex-U.S. sales, taurolidine gel formulation, and future medical device applications)—up from the prior $120M—and ~141M fully-diluted shares outstanding—including issuance of about 35M more shares due to warrant exercises and further stock issuances—as of end-2019. Our valuation of Neutrolin has risen to $350M from the previous $300M, based on higher peak sales potential." (1/18/2019)
Has CorMedix been receiving favorable news coverage?
News coverage about CRMD stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CorMedix earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
Are investors shorting CorMedix?
CorMedix saw a increase in short interest in February. As of February 28th, there was short interest totalling 14,448,495 shares, an increase of 4.3% from the February 15th total of 13,855,438 shares. Based on an average daily volume of 2,443,197 shares, the short-interest ratio is presently 5.9 days. Currently, 14.1% of the shares of the stock are short sold. View CorMedix's Current Options Chain.
Who are some of CorMedix's key competitors?
Some companies that are related to CorMedix include ANI Pharmaceuticals (ANIP), Nightstar Therapeutics (NITE), Mesoblast (MSB), Resverlogix (RVX), ProQR Therapeutics (PRQR), G1 Therapeutics (GTHX), Emerald Health Therapeutics (EMH), GlycoMimetics (GLYC), Theratechnologies (TH), Biotest (BIO), NuCana (NCNA), Polynovo (PNV), Oxford BioMedica (OXB), Senesco Technologies (ELOX) and Innate Pharma (IPHYF).
What other stocks do shareholders of CorMedix own?
Who are CorMedix's key executives?
CorMedix's management team includes the folowing people:
- Mr. Khoso Baluch, CEO & Director (Age 61)
- Mr. Robert W. Cook, Chief Financial Officer (Age 63)
- Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 75)
- Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 40)
- Dr. Paul Chew, Consultant Advisor Chief Medical Officer
Who are CorMedix's major shareholders?
CorMedix's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.52%), Geode Capital Management LLC (0.65%), Geode Capital Management LLC (0.65%), Bank of New York Mellon Corp (0.14%), Steward Partners Investment Advisory LLC (0.07%) and Wealthstreet Investment Advisors LLC (0.05%). Company insiders that own CorMedix stock include Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Institutional Ownership Trends for CorMedix.
Which institutional investors are buying CorMedix stock?
CRMD stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, Geode Capital Management LLC, Geode Capital Management LLC, Creative Planning, Wealthstreet Investment Advisors LLC, Millennium Management LLC and Steward Partners Investment Advisory LLC. Company insiders that have bought CorMedix stock in the last two years include Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Insider Buying and Selling for CorMedix.
How do I buy shares of CorMedix?
Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CorMedix's stock price today?
One share of CRMD stock can currently be purchased for approximately $1.68.
How big of a company is CorMedix?
CorMedix has a market capitalization of $176.92 million.
What is CorMedix's official website?
How can I contact CorMedix?
CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.
MarketBeat Community Rating for CorMedix (NYSEAMERICAN CRMD)
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
